Gary Reznik, MD
Cardiovascular Disease · Los Angeles, CANPI 1043244296
Payments from drug & device makers
Across 1,107 payments — averaging $86.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$46K
- Amarin Pharma, Inc.$30K
- Amgen$2K
- AbbVie$1K
- Novartis$1K
- AstraZeneca$1K
- plus $14K from 54 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$67,29070%
- Travel & lodging$2,3642%
- Food & beverage$26,15927%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$43,753
- Vascepa$27,855
- MyCareLink$275
- Veltassa$200
- Visia AF$148
- MyCareLink Smart$126
- Kerendia$125
- LINQ II$116
- ELIQUIS$116
- Micra$115
- AURORA EV-ICD MRI SURESCAN$102
How this compares
$96,118 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 1,751 | $1,838,391 |
| XareltoRivaroxaban | 1,509 | $919,997 |
| OzempicSemaglutide | 614 | $591,977 |
| Repatha SureclickEvolocumab | 999 | $560,013 |
| EdarbiAzilsartan Medoxomil | 2,142 | $558,463 |
| VascepaIcosapent Ethyl | 1,469 | $532,884 |
| EntrestoSacubitril/Valsartan | 744 | $531,415 |
| CreonLipase/Protease/Amylase | 300 | $369,661 |
| Pitavastatin Calcium | 1,564 | $327,251 |
| Icosapent Ethyl | 1,850 | $306,019 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 1,144 | $284,803 |
| EliquisApixaban | 352 | $225,021 |
| JardianceEmpagliflozin | 321 | $207,554 |
| LivaloPitavastatin Calcium | 467 | $166,760 |
| RybelsusSemaglutide | 160 | $166,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $711 | $1,863,7991,774 claims |
| Johnson & JohnsonXarelto, Procrit | $45,854 | $965,5041,538 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $178 | $843,2663,286 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $606 | $823,764821 claims |
| NovartisEntresto | $1,381 | $531,415744 claims |
| AbbVieCreon, Linzess | $1,406 | $524,534583 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Jentadueto Xr | $398 | $500,920849 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $1,090 | $268,708481 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $301 | $248,314770 claims |
| PfizerEliquis | $393 | $225,021352 claims |
| MerckVerquvo, Janumet Xr, Janumet | $278 | $170,647285 claims |
| GSKTrelegy Ellipta | $700 | $94,522145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Kalyanam ShivkumarLos Angeles$2.9M
- Priscilla HsueLos Angeles$2.3M
- Cathleen Bairey-MerzLos Angeles$1.4M
- Somjot BrarLos Angeles$1.2M
- Freny ModyLos Angeles$960K
- Jamil AboulhosnLos Angeles$683K
- Parveen GargLos Angeles$653K
- Karol WatsonLos Angeles$553K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.